Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.65 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29803977 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17568786 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13901805 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18125984 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13986328 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL24146588 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9970446 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL22393059 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL20483753 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL29380625 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260115216-A1 | NUCLEIC ACID PRECURSOR | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4704854-A2 | PRMT INHIBITOR COMPOUNDS AND THE USES THEREOF | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | UNIV MINNESOTA (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4045498-B1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| WO-2025043152-A1 | METHODS OF DEALKENYLATIVE AMINATION AND AZIDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2004013300-A2 | COMPOUNDS WITH THE BICYCLO[4.2.1]NONANE SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | GILEAD PHARMASSET LLC | 2002-10-31 | — | — | US | disclosed |
| US-6326490-B1 | ANTIPROLIFERATION AGENTS OR ANTICARCINOGENIC AGENTS | PHARMASSET, LTD. | 2001-12-04 | — | — | US | disclosed |
| US-5700786-A | Analogues of adenosine 5'diphosphate and pharmaceutical compositions thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-12-23 | — | — | US | disclosed |
| US-5658890-A | INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-19 | — | — | US | disclosed |
| US-5569650-A | C-nucleoside isosters of analogs thereof and pharmaceutical compositions | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-10-29 | — | — | US | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| US-4056673-A | VIRICIDE, ANTINEOPLASTIC | HOFFMANN-LA ROCHE INC. (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | PI4KA 2171/4885PI4K2B 2027/4885PI4K2A 2663/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | PI4KA 3880/4885PI4K2B 4159/4885PI4K2A 3812/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | PI4KA 1587/4885PI4K2B 1126/4885PI4K2A 1157/4885 |
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | PI4KA 2154/4885PI4K2B 2299/4885PI4K2A 2633/4885 |
| US-20260115216-A1 | NUCLEIC ACID PRECURSOR | NSUN2, POLRMT, SSU72 | PI4KA 1774/4885PI4K2B 1586/4885PI4K2A 1567/4885 |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | PC, GOT2, PCK2 | PI4KA 543/4885PI4K2B 701/4885PI4K2A 645/4885 |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | NSUN2, SARS1, RNMT | PI4KA 2862/4885PI4K2B 2542/4885PI4K2A 3099/4885 |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | PI4KA 857/4885PI4K2B 1224/4885PI4K2A 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.